Aurisco Pharmaceutical Co.,Ltd. (SHSE: 605116)
Health Care · Pharmaceuticals · CN
CN¥19.95
-4.22% today · -16.5% 1Y
Aurisco Pharmaceutical Co.,Ltd. (SHSE: 605116) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.20B and employs 2,026 people.
Over the last twelve months the share price has lost 16.5%, trading between 18.09 and 35.58.
Tweenvest scores Aurisco Pharmaceutical Co.,Ltd. across four factors: quality 79/100, value 60/100, growth 84/100, dividend 22/100. Its strongest factor is growth.
605116 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.20B
- Revenue (TTM)
- $244.26M
- P/E
- 20.71
- EPS
- 0.96
- Dividend yield
- 1.70%
- Beta (5Y)
- -0.36
- 52-week high
- CN¥35.58
- 52-week low
- CN¥18.09
- Avg volume (3M)
- —
- Shares outstanding
- 403.41M
- Employees
- 2,026
- Next earnings
- —
About Aurisco Pharmaceutical Co.,Ltd.
Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, and chronic obstructive pulmonary disease; eplerenone preparations are used for the treatment of hypertension and heart failure; bepedalic acid preparations are used for the treatment of hypercholesterolemia or atherosclerotic cardiovascular diseases; tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B; pregabalin preparations are used to treat neuropathic pain, fibromyalgia, epilepsy, etc.; brivaracetam preparations are used to treat epilepsy; abiraterone acetate and enzalutamide preparation preparations for the treatment of prostate cancer; and dydrogesterone preparations are used to treat dysmenorrhea, endometriosis, irregular menstrual cycle, etc. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.
- ISIN
- CNE1000042S4
- Founded
- 1998
- Listed since
- Sep 21, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.35 | +0.16% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.